Our finding that SFKs are key mediators of PRL-enhanced estrogen-induced growth in stiff, but not in compliant matrices begins to reconcile the apparent conflict between evidence for PRL activity and activated STAT5 in outcomes of ERα+ breast cancer [17, 18, 36–38]. The gene discussed is ESR1; the disease is breast cancer.